Develop new therapies from our novel, early stage drug discovery programmes
We offer access to:
- A portfolio of drug targets that are de-risked via
proof of concept studies - Expertise in assay development and screening against
a range of new and exciting targets for drug discovery - Licensing options are available at any stage up to
drug-like leads
What we offer
We de-risk novel targets via proof of concept studies, demonstrating that they are druggable with strong evidence for disease association by providing:
- Validated HTS assays for a wide range of targets, including unique or first in class
- Good quality progressable hits derived from a high quality compound library
- SAR development versus the target
- Drug-like lead compounds displaying potency, selectivity and favourable ADMET profiles
- Confidence that a clinical candidate can be identified
- Proof of Concept (PoC) in cells and/or animals to link target to disease
- Confidence that hitting the target has no significant adverse effect
Working with us
Work with our Centre for Therapeutics Discovery to take promising molecules and antibodies down the path to clinical application.
For more information please contact Justin Bryans, Director of Drug Discovery, or Contact Us.
